Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piaggi

Showing results (371-380 of 383) with videos related to

Pageof 39
Sort By:
Oncology Letters|May 29, 2018
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experienceCristina Romei, Alessia Tacito, Eleonora Molinaro, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Poupak Fallahi, et al.
Oncology Reports|March 9, 2018
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivoSilvia Martina Ferrari, Guido Bocci, Teresa Di Desidero, et al.
The Journal of Clinical Endocrinology and Metabolism|October 26, 2019
Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian CenterEleonora Molinaro, Maria Cristina Campopiano, Letizia Pieruzzi, et al.
Cell Reports|September 5, 2019
Peptide/Receptor Co-evolution Explains the Lipolytic Function of the Neuropeptide TLQP-21Bhavani S Sahu, Pedro Rodriguez, Megin E Nguyen, et al.
Diabetes Care|May 20, 2025
Human Physiologic Responses to Insulin in Indigenous Americans Identify a Metabolic Susceptibility Profile Linked to DiabetesVenkatesh L Murthy, Paolo Piaggi, Phillip Lin, et al.
Molecular and Cellular Endocrinology|June 17, 2014
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Diabetes|August 7, 2015
ABCC8 R1420H Loss-of-Function Variant in a Southwest American Indian Community: Association With Increased Birth Weight and Doubled Risk of Type 2 DiabetesLeslie J Baier, Yunhua Li Muller, Maria Sara Remedi, et al.
Oncology Reports|March 9, 2018
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivoSilvia Martina Ferrari, Guido Bocci, Teresa Di Desidero, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Pageof 39

Showing results (371-380 of 383) with videos related to

Sort By:
Pageof 39
Oncology Letters|May 29, 2018
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experienceCristina Romei, Alessia Tacito, Eleonora Molinaro, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Poupak Fallahi, et al.
Oncology Reports|March 9, 2018
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivoSilvia Martina Ferrari, Guido Bocci, Teresa Di Desidero, et al.
The Journal of Clinical Endocrinology and Metabolism|October 26, 2019
Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian CenterEleonora Molinaro, Maria Cristina Campopiano, Letizia Pieruzzi, et al.
Cell Reports|September 5, 2019
Peptide/Receptor Co-evolution Explains the Lipolytic Function of the Neuropeptide TLQP-21Bhavani S Sahu, Pedro Rodriguez, Megin E Nguyen, et al.
Diabetes Care|May 20, 2025
Human Physiologic Responses to Insulin in Indigenous Americans Identify a Metabolic Susceptibility Profile Linked to DiabetesVenkatesh L Murthy, Paolo Piaggi, Phillip Lin, et al.
Molecular and Cellular Endocrinology|June 17, 2014
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Diabetes|August 7, 2015
ABCC8 R1420H Loss-of-Function Variant in a Southwest American Indian Community: Association With Increased Birth Weight and Doubled Risk of Type 2 DiabetesLeslie J Baier, Yunhua Li Muller, Maria Sara Remedi, et al.
Oncology Reports|March 9, 2018
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivoSilvia Martina Ferrari, Guido Bocci, Teresa Di Desidero, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Pageof 39